Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Finance

Down rounds don’t aid post-IPO performance

Neither private down rounds nor IPO step-downs correlate with market performance after IPOs

By Stephen Hansen, Director of Biopharma Intelligence
October 10, 2024 10:52 PM UTC

An analysis of the 2024 class of biotech IPOs shows that taking a down round ahead of or at the IPO doesn’t necessarily translate into aftermarket performance. 

A selection of 16 companies that went public on NASDAQ and NYSE this year shows that the top performers had small up rounds at both their last private raise and the IPO. These include oncolytic immunotherapy play CG Oncology Inc. (NASDAQ:CGON), cardiometabolic company MBX Biosciences Inc. (NASDAQ:MBX) and bispecifics company Bicara Therapeutics Inc. (NASDAQ:BCAX)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bicara Therapeutics Inc.

Boundless Bio Inc.

Cg Oncology Inc.

Kyverna Therapeutics Inc.

Mbx Biosciences Inc.

BCIQ Target Profiles

CD19